🚀
Enjoy a 7-Day Free Trial Thru May 02, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
HOOKIPA Pharma Inc (NAS:HOOK)
News
HOOKIPA Pharma Inc
NAS
:HOOK (USA) Â
$ 0.85
+0.085 (+11.11%)
10:08 PM EST
P/E:
At Loss
P/B:
0.93
Market Cap:
$ 84.11M
Enterprise V:
$ -34.84M
Volume:
10.35M
Avg Vol (2M):
563.55K
Warning! GuruFocus detected 4 Severe warning signs with HOOK.
Try a 7-Day Free Trial
to check it out.
Volume:
10.35M
Market Cap $:
84.11M
PE Ratio:
At Loss
Avg Vol (2M):
563.55K
Enterprise Value $:
-34.84M
PB Ratio:
0.93
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
HOOKIPA Pharma Inc (NAS:HOOK) Stock News, Headlines & Updates
HOOKIPA Pharma Inc Stock News from GuruFocus
Total 105
1
2
3
Apr 24, 2024
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
Marketwired
•
7:00am
Apr 16, 2024
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Marketwired
•
4:00pm
Apr 10, 2024
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
Marketwired
•
7:00am
Nov 09, 2023
HOOKIPA Pharma Inc. Reports Increased Revenue and Higher R&D Expenses in Q3 2023
GuruFocus Research
•
7:39am
Nov 03, 2023
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
Marketwired
•
12:00pm
Nov 02, 2023
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
Marketwired
•
4:00pm
Oct 22, 2023
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
GlobeNewswire
•
11:00am
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
Marketwired
•
6:00am
Oct 18, 2023
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
Marketwired
•
7:00am
Sep 13, 2023
HOOKIPA Announces Executive Leadership Change
Marketwired
•
8:00am
Sep 12, 2023
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Marketwired
•
7:00am
Sep 06, 2023
HOOKIPA Pharma to participate in upcoming investor conferences in September
Marketwired
•
7:00am
Aug 10, 2023
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Marketwired
•
7:00am
Aug 03, 2023
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
Marketwired
•
7:00am
Jul 04, 2023
Insider Buying: CFO Reinhard Kandera Acquires 12,000 Shares of HOOKIPA Pharma Inc
GuruFocus Research
•
5:01am
Feb 13, 2023
HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers
sperokesalga
•
6:00am
Feb 07, 2023
HOOKIPA to Present at the SVB Securities Global Biopharma Conference
Stock market mentor
•
6:00am
Dec 15, 2022
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors
Value_Insider
•
6:00am
Nov 30, 2022
HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit
Value_Insider
•
6:00am
Nov 07, 2022
HOOKIPA Pharma to Report Third Quarter 2022 Financial Results and Corporate Updates on November 14, 2022
Value_Insider
•
6:00am
Nov 02, 2022
HOOKIPA to Participate in the Sidoti Micro-Cap Virtual Conference
Value_Insider
•
6:00am
Oct 20, 2022
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
Value_Insider
•
6:00am
Aug 11, 2022
HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
PurpleRose
•
7:00am
Aug 04, 2022
HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022
PurpleRose
•
7:00am
Jul 25, 2022
FDA accepts HOOKIPA's Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
PurpleRose
•
7:00am
Jul 08, 2022
HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022
GuruFocusNews
•
9:02am
Jul 05, 2022
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
GuruFocusNews
•
5:16pm
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
GuruFocusNews
•
8:21am
Jul 01, 2022
HOOKIPA Announces Executive Leadership Changes
GuruFocusNews
•
8:33am
Jun 28, 2022
HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022
GuruFocusNews
•
9:01am
Jun 25, 2022
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
GuruFocusNews
•
5:16pm
Jun 21, 2022
HOOKIPA Announces Executive Leadership Changes
GuruFocusNews
•
8:29am
Jun 19, 2022
HOOKIPA to Participate in the JMP Securities Life Sciences Conference
GuruFocusNews
•
6:22am
Jun 15, 2022
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
GuruFocusNews
•
5:16pm
Jun 09, 2022
HOOKIPA to Participate in the JMP Securities Life Sciences Conference
GuruFocusNews
•
6:19am
Jun 05, 2022
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
GuruFocusNews
•
5:15pm
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
GuruFocusNews
•
8:17am
Jun 03, 2022
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
GuruFocusNews
•
6:16am
May 26, 2022
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
GuruFocusNews
•
5:14pm
May 16, 2022
HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights
GuruFocusNews
•
6:29am
Total 105
1
2
3
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news